Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVENT-TN
PACTR202509597624973Phase 4Not yet recruiting
- Sponsor
- University Military Hospital of Sfax
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ezetimibe and atorvastatin in dyslipidemia and cardiac morbidity (2 arms), sponsored by University Military Hospital of Sfax. Primary endpoint: Change in LDL-C level. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
ezetimibeatorvastatin
03
Conditions
dyslipidemiacardiac morbidity
Beyond the preview
Go deeper on PACTR202509597624973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202509597624973.